Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Chondrosarcoma | Research

Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma

Authors: Alexander L. Lazarides, Bijan Abar, Bruce Leckey, John T. Martin, Evelyna G. Kliassov, Brian E. Brigman, William C. Eward, Diana M. Cardona, Julia D. Visgauss

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cartilaginous neoplasms can be challenging to grade; there is a need to create an evidence-based rubric for grading. The goal of this study was to identify histopathologic features of chondrosarcoma that were associated with 5-year survival and to compare these to traditional patient, tumor and treatment variables.

Methods

This was a retrospective review of all patients undergoing surgical resection of a primary chondrosarcoma with at least 2 years of follow up. All specimens were independently reviewed by two pathologists and histopathologic features scored. Univariate and multivariate analyses were performed utilizing Kaplan Meier and proportional hazards methods to identify variables associated with 5-year disease specific survival (DSS) and disease free survival (DFS).

Results

We identified 51 patients with an average follow up of 49 months eligible for inclusion. 30% of tumors were low grade, 45% were intermediate grade, and 25% were high grade. In a univariate analysis considering histopathologic factors, higher tumor mitotic rate (HR 8.9, p < 0.001), tumor dedifferentiation (HR 7.3, p < 0.001), increased tumor cellularity (HR 5.8, p = 0.001), increased tumor atypia (HR 5.8, p = 0.001), LVI (HR 4.7, p = 0.04) and higher tumor necrosis (HR 3.7, p = 0.02) were all associated with worse 5-year DSS. In a multivariate analysis controlling for potentially confounding variables, higher tumor necrosis was significantly associated with disease specific survival survival (HR 3.58, p = 0.035); none of the factors were associated with DFS.

Conclusions

This study provides an evidence-based means for considering histopathologic markers and their association with prognosis in chondrosarcoma. Our findings suggest that necrosis and LVI warrant further study.
Literature
1.
go back to reference Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818–31 Epub 1977/08/01.CrossRefPubMed Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818–31 Epub 1977/08/01.CrossRefPubMed
2.
go back to reference Ethun CG, Lopez-Aguiar AG, Switchenko JM, Gillespie TW, Delman KA, Staley CA, et al. The prognostic value of lymphovascular invasion in truncal and extremity soft tissue sarcomas: an analysis from the national cancer database. Ann Surg Oncol. 2019;26(13):4723–9 Epub 2019/09/11.CrossRefPubMedPubMedCentral Ethun CG, Lopez-Aguiar AG, Switchenko JM, Gillespie TW, Delman KA, Staley CA, et al. The prognostic value of lymphovascular invasion in truncal and extremity soft tissue sarcomas: an analysis from the national cancer database. Ann Surg Oncol. 2019;26(13):4723–9 Epub 2019/09/11.CrossRefPubMedPubMedCentral
3.
go back to reference Gusho CA, Miller I, Clayton B, Colman MW, Gitelis S, Blank AT. The prognostic significance of lymphovascular tumor invasion in localized high-grade osteosarcoma: outcomes of a single institution over 10 years. J Surg Oncol. 2021;123(7):1624–32 Epub 2021/02/24.CrossRefPubMed Gusho CA, Miller I, Clayton B, Colman MW, Gitelis S, Blank AT. The prognostic significance of lymphovascular tumor invasion in localized high-grade osteosarcoma: outcomes of a single institution over 10 years. J Surg Oncol. 2021;123(7):1624–32 Epub 2021/02/24.CrossRefPubMed
4.
go back to reference picci. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. 1997.CrossRef picci. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. 1997.CrossRef
5.
go back to reference Picci P, Bohling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol. 1997;15(4):1553–9 Epub 1997/04/01.CrossRefPubMed Picci P, Bohling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol. 1997;15(4):1553–9 Epub 1997/04/01.CrossRefPubMed
6.
go back to reference Salah S, Lewin J, Amir E, Abdul RA. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treat Rev. 2018;69:1–10 Epub 2018/05/31.CrossRefPubMed Salah S, Lewin J, Amir E, Abdul RA. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treat Rev. 2018;69:1–10 Epub 2018/05/31.CrossRefPubMed
7.
go back to reference Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12(2):423–31 Epub 1994/02/01.CrossRefPubMed Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12(2):423–31 Epub 1994/02/01.CrossRefPubMed
8.
go back to reference Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106(12):2682–91.CrossRefPubMed Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106(12):2682–91.CrossRefPubMed
9.
go back to reference Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 1986;68(8):1197–205 Epub 1986/10/01.CrossRefPubMed Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am. 1986;68(8):1197–205 Epub 1986/10/01.CrossRefPubMed
10.
go back to reference Strotman PK, Reif TJ, Kliethermes SA, Sandhu JK, Nystrom LM. Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001–2011). J Surg Oncol. 2017;116(2):252–7 Epub 2017/04/19.CrossRefPubMed Strotman PK, Reif TJ, Kliethermes SA, Sandhu JK, Nystrom LM. Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001–2011). J Surg Oncol. 2017;116(2):252–7 Epub 2017/04/19.CrossRefPubMed
11.
go back to reference Aigner T, Unni KK. Is dedifferentiated chondrosarcoma a ‘de-differentiated’ chondrosarcoma? J Pathol. 1999;189(4):445–7 Epub 2000/01/12.CrossRefPubMed Aigner T, Unni KK. Is dedifferentiated chondrosarcoma a ‘de-differentiated’ chondrosarcoma? J Pathol. 1999;189(4):445–7 Epub 2000/01/12.CrossRefPubMed
12.
go back to reference Weinschenk RC, Wang WL, Lewis VO. Chondrosarcoma. J Am Acad Orthop Surg. 2021;29(13):553–62 Epub 2021/02/18.CrossRefPubMed Weinschenk RC, Wang WL, Lewis VO. Chondrosarcoma. J Am Acad Orthop Surg. 2021;29(13):553–62 Epub 2021/02/18.CrossRefPubMed
13.
go back to reference de Andrea CE, Kroon HM, Wolterbeek R, Romeo S, Rosenberg AE, De Young BR, et al. Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol. 2012;25(9):1275–83 Epub 2012/05/05.CrossRefPubMedPubMedCentral de Andrea CE, Kroon HM, Wolterbeek R, Romeo S, Rosenberg AE, De Young BR, et al. Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol. 2012;25(9):1275–83 Epub 2012/05/05.CrossRefPubMedPubMedCentral
14.
go back to reference Roitman PD, Farfalli GL, Ayerza MA, Muscolo DL, Milano FE, Aponte-Tinao LA. Is needle biopsy clinically useful in preoperative grading of central chondrosarcoma of the pelvis and long bones? Clin Orthop Relat Res. 2017;475(3):808–14 Epub 2016/02/18.CrossRefPubMed Roitman PD, Farfalli GL, Ayerza MA, Muscolo DL, Milano FE, Aponte-Tinao LA. Is needle biopsy clinically useful in preoperative grading of central chondrosarcoma of the pelvis and long bones? Clin Orthop Relat Res. 2017;475(3):808–14 Epub 2016/02/18.CrossRefPubMed
15.
go back to reference Ferrer-Santacreu EM, Ortiz-Cruz EJ, Diaz-Almiron M, Pozo Kreilinger JJ. Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: clinical and radiological criteria-a follow-up. J Oncol. 2016;2016:8262079 Epub 20160223.CrossRefPubMedPubMedCentral Ferrer-Santacreu EM, Ortiz-Cruz EJ, Diaz-Almiron M, Pozo Kreilinger JJ. Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: clinical and radiological criteria-a follow-up. J Oncol. 2016;2016:8262079 Epub 20160223.CrossRefPubMedPubMedCentral
16.
go back to reference Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovee JV, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50–7.CrossRefPubMed Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovee JV, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50–7.CrossRefPubMed
17.
go back to reference Thorkildsen J, Taksdal I, Bjerkehagen B, Norum OJ, Myklebust TA, Zaikova O. Risk stratification for central conventional chondrosarcoma of bone: a novel system predicting risk of metastasis and death in the Cancer Registry of Norway cohort. J Surg Oncol. 2020;121(7):1115–25 Epub 2020/03/07.CrossRefPubMed Thorkildsen J, Taksdal I, Bjerkehagen B, Norum OJ, Myklebust TA, Zaikova O. Risk stratification for central conventional chondrosarcoma of bone: a novel system predicting risk of metastasis and death in the Cancer Registry of Norway cohort. J Surg Oncol. 2020;121(7):1115–25 Epub 2020/03/07.CrossRefPubMed
18.
go back to reference Compton ML, Cates JMM. Evidence-based tumor staging of skeletal chondrosarcoma. Am J Surg Pathol. 2020;44(1):111–9.CrossRefPubMed Compton ML, Cates JMM. Evidence-based tumor staging of skeletal chondrosarcoma. Am J Surg Pathol. 2020;44(1):111–9.CrossRefPubMed
19.
go back to reference Antonescu CR, Argani P, Erlandson RA, Healey JH, Ladanyi M, Huvos AG. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer. 1998;83(8):1504–21.CrossRefPubMed Antonescu CR, Argani P, Erlandson RA, Healey JH, Ladanyi M, Huvos AG. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer. 1998;83(8):1504–21.CrossRefPubMed
20.
go back to reference Bovee JV, Cleton-Jansen AM, Rosenberg C, Taminiau AH, Cornelisse CJ, Hogendoorn PC. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189(4):454–62 Epub 2000/01/12.CrossRefPubMed Bovee JV, Cleton-Jansen AM, Rosenberg C, Taminiau AH, Cornelisse CJ, Hogendoorn PC. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189(4):454–62 Epub 2000/01/12.CrossRefPubMed
21.
go back to reference Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51(10):899–909 Epub 2012/06/08.CrossRefPubMed Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51(10):899–909 Epub 2012/06/08.CrossRefPubMed
22.
go back to reference Lucas CG, Grenert JP, Horvai A. Targeted next-generation sequencing identifies molecular and genetic events in dedifferentiated chondrosarcoma. Arch Pathol Lab Med. 2021;145(8):1009–17 Epub 2020/11/05.CrossRefPubMed Lucas CG, Grenert JP, Horvai A. Targeted next-generation sequencing identifies molecular and genetic events in dedifferentiated chondrosarcoma. Arch Pathol Lab Med. 2021;145(8):1009–17 Epub 2020/11/05.CrossRefPubMed
23.
go back to reference Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011;117(6):1279–87 Epub 2011/03/08.CrossRefPubMed Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011;117(6):1279–87 Epub 2011/03/08.CrossRefPubMed
24.
go back to reference Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res. 2003;9(3):1211–7 Epub 2003/03/13.PubMed Morioka H, Weissbach L, Vogel T, Nielsen GP, Faircloth GT, Shao L, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res. 2003;9(3):1211–7 Epub 2003/03/13.PubMed
25.
go back to reference Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004;86(11):2412–8 Epub 2004/11/04.CrossRefPubMed Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004;86(11):2412–8 Epub 2004/11/04.CrossRefPubMed
26.
go back to reference Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670–80 Epub 2011/12/20.CrossRefPubMed Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670–80 Epub 2011/12/20.CrossRefPubMed
27.
go back to reference Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007;31(12):1825–33 Epub 2007/11/29.CrossRefPubMed Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol. 2007;31(12):1825–33 Epub 2007/11/29.CrossRefPubMed
28.
go back to reference Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240(2):306–12 Epub 2004/07/27.CrossRefPubMedPubMedCentral Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240(2):306–12 Epub 2004/07/27.CrossRefPubMedPubMedCentral
29.
go back to reference Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol. 2005;174(6):2181–5 Epub 2005/11/11.CrossRefPubMed Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol. 2005;174(6):2181–5 Epub 2005/11/11.CrossRefPubMed
Metadata
Title
Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
Authors
Alexander L. Lazarides
Bijan Abar
Bruce Leckey
John T. Martin
Evelyna G. Kliassov
Brian E. Brigman
William C. Eward
Diana M. Cardona
Julia D. Visgauss
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Chondrosarcoma
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11022-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine